Free Trial
NASDAQ:ZVRA

Zevra Therapeutics (ZVRA) Stock Price, News & Analysis

$4.63
+0.01 (+0.22%)
(As of 05/22/2024 ET)
Today's Range
$4.59
$4.68
50-Day Range
$4.50
$6.15
52-Week Range
$3.89
$7.28
Volume
113,809 shs
Average Volume
238,497 shs
Market Capitalization
$193.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.50

Zevra Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
321.2% Upside
$19.50 Price Target
Short Interest
Bearish
6.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.54) to ($0.13) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.61 out of 5 stars

Medical Sector

858th out of 921 stocks

Pharmaceutical Preparations Industry

366th out of 394 stocks

ZVRA stock logo

About Zevra Therapeutics Stock (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

ZVRA Stock Price History

ZVRA Stock News Headlines

See More Headlines
Receive ZVRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/28/2024
Today
5/22/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ZVRA
Employees
65
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.50
High Stock Price Target
$25.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+321.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-46,050,000.00
Net Margins
-181.76%
Pretax Margin
-176.46%

Debt

Sales & Book Value

Annual Sales
$27.46 million
Book Value
$1.17 per share

Miscellaneous

Free Float
40,849,000
Market Cap
$193.77 million
Optionable
Optionable
Beta
1.87
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Neil F. McFarlane (Age 51)
    President, CEO & Director
    Comp: $503.77k
  • Ms. Christal M. M. Mickle M.A. (Age 45)
    Co-Founder & Chief Development Officer
    Comp: $622.36k
  • Mr. R. LaDuane Clifton CPA (Age 52)
    CFO, Secretary & Treasurer
    Comp: $658.43k
  • Mr. Joshua M. Schafer M.B.A. (Age 52)
    Chief Commercial Officer & Executive VP of Business Development
    Comp: $766.07k
  • Dr. Sven Guenther Ph.D. (Age 52)
    Chief Scientific Officer
    Comp: $497.26k
  • Ms. Nichol L. Ochsner
    Vice President of Investor Relations & Corporate Communications
  • Dr. Christopher M. Lauderback Ph.D. (Age 49)
    Senior Vice President of Manufacturing
  • Dr. Rene A. Braeckman Ph.D.
    Senior Vice President of Clinical Development
  • Dr. Daniel Gallo Ph.D.
    Senior Vice President of Medical Affairs & Advocacy
  • Dr. Adrian Quartel FFPM (Age 63)
    M.D., Chief Medical Officer

ZVRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Zevra Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zevra Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZVRA shares.
View ZVRA analyst ratings
or view top-rated stocks.

What is Zevra Therapeutics' stock price target for 2024?

6 brokerages have issued 1 year price targets for Zevra Therapeutics' stock. Their ZVRA share price targets range from $15.00 to $25.00. On average, they expect the company's share price to reach $19.50 in the next twelve months. This suggests a possible upside of 321.2% from the stock's current price.
View analysts price targets for ZVRA
or view top-rated stocks among Wall Street analysts.

How have ZVRA shares performed in 2024?

Zevra Therapeutics' stock was trading at $6.55 at the beginning of the year. Since then, ZVRA stock has decreased by 29.3% and is now trading at $4.63.
View the best growth stocks for 2024 here
.

When is Zevra Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our ZVRA earnings forecast
.

How were Zevra Therapeutics' earnings last quarter?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) announced its quarterly earnings results on Thursday, March, 28th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.20. The firm earned $13.22 million during the quarter, compared to analysts' expectations of $13.35 million. Zevra Therapeutics had a negative net margin of 181.76% and a negative trailing twelve-month return on equity of 82.55%.

Who are Zevra Therapeutics' major shareholders?

Zevra Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.92%), Janney Montgomery Scott LLC (1.52%), Retirement Planning Co of New England Inc. (0.99%), Mystic Asset Management Inc. (0.61%), Jacobs Levy Equity Management Inc. (0.08%) and IFG Advisors LLC (0.04%). Insiders that own company stock include Corey Michael Watton, John B Bode, Joshua Schafer, Matthew R Plooster, R Laduane Clifton, Richard W Pascoe, Tamara A Seymour and Timothy J Sangiovanni.
View institutional ownership trends
.

How do I buy shares of Zevra Therapeutics?

Shares of ZVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ZVRA) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners